Loading the records…
Loading the records…
HR3491 (DeOndra Dixon INCLUDE Project Act) authorizes a Down syndrome research program at NIH but appropriates zero funding. With only 5 procedural actions over a year and stalled committee markup, the bill has no near-term market impact. No public companies are directly affected.
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
No publicly traded companies have direct revenue exposure to this authorization-only bill. The research program would benefit academic grantees, not corporate entities. Investors should not adjust positions based on this legislation.
The bill, introduced May 2025, authorizes the NIH Director to carry out the INCLUDE Project for Down syndrome research. Its status remains 'Reported out of committee — awaiting floor action' after a unanimous 46-0 committee vote on May 21, 2026. However, the bill explicitly does not appropriate any funds — it merely authorizes a program structure. No dollar amounts appear in the text, and the action history shows nearly a year elapsed between introduction and the single committee markup, indicating low legislative priority. Authorizations without appropriations have no binding effect on federal spending or private sector revenue. The research program, if eventually funded through separate appropriations, would flow through NIH grants to academic institutions and research hospitals, not directly to publicly traded companies. No pharmaceutical, biotech, or diagnostic company is named in the bill or its findings. Related bills (S891, HR1768) cover broader healthcare topics but lack specific Down syndrome funding mechanisms. With no market catalyst, no funding stream, and no named corporate beneficiaries, this bill registers as procedural noise for investors.
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Multiple independent sources confirm this signal’s market thesis
Matched on shared policy language across AI analyses, with ticker & timing weight
Executive orders & memoranda affecting the same sectors or companies
This executive order establishes a Women's Health Division within the NIH to coordinate and accelerate research on understudied women's health conditions, and creates a White House Women's Health Task Force to drive policy reforms and translation of research into clinical practice across federal agencies. It directs specific agencies to prioritize research, data collection, and translation into prevention, diagnosis, and treatment, with a focus on all life stages from infancy through aging.
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Free — no credit card
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →